Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) announce that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines.
Read the full article: Sun Pharma Signs Definitive Agreement to Acquire Organon //
Source: https://www.businesswire.com/news/home/20260426881370/en/Sun-Pharma-signs-Definitive-Agreement-to-Acquire-Organon